Decreased Expression of PACSIN1 in Brain Glioma Samples Predicts Poor Prognosis

Zhou Zimu; Zhang Jia; Fu Xian; Ma Rui; Ren Yuting; Wei Yuan; Wen Tianhong; Ma Mian; Liu Yinlong; Shan Enfang

doi:10.3389/fmolb.2021.696072

Decreased Expression of PACSIN1 in Brain Glioma Samples Predicts Poor Prognosis

Front Mol Biosci. 2021 Aug 5:8:696072. doi: 10.3389/fmolb.2021.696072. eCollection 2021.

Authors

Zhou Zimu^{1

2}, Zhang Jia¹, Fu Xian³, Ma Rui¹, Ren Yuting¹, Wei Yuan¹, Wen Tianhong¹, Ma Mian³, Liu Yinlong^{4

3}, Shan Enfang^{1

2}

Affiliations

¹ School of Nursing, Nanjing Medical University, Nanjing, China.
² Cancer Nursing Research Branch, Nursing Research Center, Nanjing Medical University, Nanjing, China.
³ Department of Neurosurgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, China.
⁴ Department of Neurosurgery, The Affiliated Huashan Hospital, Fudan University, Shanghai, China.

Abstract

Gliomas are the most severe brain tumours with a poor prognosis. Although surgery, postoperative radiotherapy and chemotherapy can improve the survival rate of glioma patients, the prognosis of most glioma patients is still poor. In recent years, the influence of gene-targeted therapy on gliomas has been gradually discovered, and intervening the occurrence and development of brain gliomas from the perspective of the gene will significantly improve treatment prognosis. Protein Kinase C and Casein Kinase Substrate in Neurons 1 (PACSIN1) is a member of the conserved peripheral membrane protein family in eukaryotes. Improper expression of PACSIN1 can lead to neurological diseases such as Huntington's disease and schizophrenia. However, its relationship with tumours or even gliomas has not been explored. The study aims to explore PACSIN1 as a prognostic factor that can predict overall survival (OS) for gliomas. We collected the data from CGGA, TCGA, GEO databases and the pathological glioma tissue specimens from 15 clinical glioma patients surgically resected. The differential expression of PACSIN1 in various clinical indicators, the genes related to PACSIN1 expression, the prognostic value of PACSIN1 and the functional annotations and pathway analysis of differently expressed genes (DEGs) were analysed. The results revealed that PACSIN1 had low expression levels in grade IV, IDH1 wild-type and 1p/19q non-codel group gliomas, and PACSIN1 was considered a mesenchymal molecular subtype marker. PACSIN1 expression is positively correlated with OS in all gliomas and it was found that PACSIN1 influenced the occurrence and development of gliomas through synaptic transmission. The PACSIN1 expression is negatively correlated with the malignant degree of gliomas and positively associated with the OS, indicating that PACSIN1 would play an essential role in the occurrence and development of gliomas and might be a potential new biomarker and targeted therapy site for gliomas.

Keywords: PACSIN1; biomarker; glioma; os; targeted therapy.